Market Place
Sourcing Support
Imara Announces Stockholder Approval of Merger With Enliven
22 Feb 2023 //
GLOBENEWSWIRE
Enliven to enter public markets through reverse merger with Imara
15 Oct 2022 //
BIOPHARMADIVE
Enliven Therapeutics and Imara Announce Merger Agreement
13 Oct 2022 //
GLOBENEWSWIRE
Imara sells failed blood disorder drug to heart disease outfit Cardurion
10 Sep 2022 //
ENDPTS
After Disappointing Data, Imara Offloads It Sickle Cell Candidate, Shares Surge
08 Sep 2022 //
YAHOO
Imara to reduce staff by 83% amid biotech shakeout
19 Apr 2022 //
BIOPHARMADIVE
Imara flunks a pair of phase 2bs, wiping out clinical pipeline
06 Apr 2022 //
MEDCITY NEWS
Imara Reports FY 2021 Financial Results
15 Mar 2022 //
GLOBENEWSWIRE
Imara to Webcast Conference Call of FY 2021 Financial Results
08 Mar 2022 //
GLOBENEWSWIRE
Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference
10 Feb 2022 //
GLOBENEWSWIRE
FDA Clears Imara`s IND for Tovinontrine in HFpEF
25 Jan 2022 //
GLOBENEWSWIRE
Imara Presents Preclinical Data on IMR-261 at (ASH)
14 Dec 2021 //
GLOBENEWSWIRE
Imara Announces Primary Endpoint Change in the Ardent Ph2b Trial of Tovinontrine
22 Nov 2021 //
GLOBENEWSWIRE
Imara Announces Interim Analysis from Phase 2b FORTE Trial
17 Nov 2021 //
TRIALSITENEWS
Imara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial
16 Nov 2021 //
GLOBENEWSWIRE
Imara to Present Clinical and Preclinical Data at ASH 2021
04 Nov 2021 //
GLOBENEWSWIRE
Imara to Participate in Upcoming Investor Conferences
15 Sep 2021 //
GLOBENEWSWIRE
Imara Reports Second Quarter 2021 Financial Results and Business Highlights
06 Aug 2021 //
GLOBENEWSWIRE
Imara Announces Completion of Patient Enrollment in Ph2b Trial of IMR-687
05 Aug 2021 //
GLOBENEWSWIRE
Imara Announces Pricing of Public Offering
13 Jul 2021 //
GLOBENEWSWIRE
Imara Announces Launch of Proposed Public Offering
13 Jul 2021 //
GLOBENEWSWIRE
Imara Announces Appointment of Laura A. Williams to Board of Directors
30 Jun 2021 //
GLOBENEWSWIRE
Imara Announces Recipients of the Second Annual Real Impact Grants Program
17 Jun 2021 //
GLOBENEWSWIRE
JPM: Imara CEO on fighting sickle cell disease during COVID-19
13 Jan 2021 //
FIERCEBIOTECH
Imara Reports PH 2a Trial Results of IMR-687 in Adult Patients with SCD
06 Jan 2021 //
GLOBENEWSWIRE
Imara Presents IMR-687 Ph 2a Open Label Extension Case Reports on Two Patients
07 Dec 2020 //
GLOBENEWSWIRE
Imara to Present Clinical Data on IMR-687 as Monotherapy and in Combination
30 Nov 2020 //
GLOBENEWSWIRE
Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687
16 Oct 2020 //
GLOBENEWSWIRE
Imara Announces IMR-687 Granted Fast Track Designation & Rare Pediatric Disease
30 Jul 2020 //
GLOBENEWSWIRE
Imara Receives Orphan Drug Designation for IMR-687 for Beta-thalassemia
23 Jun 2020 //
GLOBENEWSWIRE
Imara Presents Positive Interim Results from Phase 2a Study of IMR-687
12 Jun 2020 //
GLOBENEWSWIRE
